IGNITE has a foundational partnership with Pfizer in the area of intravenous oncolytic cancer vaccines. Together, IGNITE and Pfizer are jointly performing research on these cutting-edge immunotherapy agents. Areas of focus include vector discovery, pharmacology-toxicology, and cancer immunotherapy combination studies.
This unique and comprehensive partnership combines the IGNITE team’s expertise in oncolytic cancer vaccines and therapeutic viruses, including viral gene therapy vectors, with Pfizer’s leadership in cancer vaccines.
Executing on the IGNITE mission will require collaborations with leading academic institutions that share our vision. We welcome research collaborations on oncolytic cancer vaccine mechanism of action studies, combination therapy regimens, novel preclinical tumor model systems, immune system interactions, and advances in manufacturing technologies.